AzTrials
AzTrials

Advanced CancerPhase 1NCT01596140

Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer

A Phase 1 study testing Vemurafenib, Everolimus and Temsirolimus in people with Advanced Cancer and Solid Tumor, run by M.D. Anderson Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied. Read more about this study

Who is it for?
Any age
Conditions the study is for
Advanced Cancer, Solid Tumor
What is being tested?
Vemurafenib, Everolimus and Temsirolimus
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
1 siteUnited States
Study dates
18 Dec 2012to 1 Jun 2020
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Confirmation of BRAF mutation-positive malignancy is required for selection of patients for vemurafenib therapy
  • Measurable or non-measurable disease by RECIST 1.1.
  • Patients with advanced cancer should be refractory to standard therapy, relapsed after standard therapy, or have no standard therapy available that improves survival by at least three months.
  • Patients must be at least 3 weeks past receiving cytotoxic therapy and at least 5 half-lives after their previous treatment or 3 weeks, whichever is shorter, after biologic therapy. Patients may receive palliative radiotherapy immediately or during treatment provided that not all target lesions are radiated.
  • ECOG performance status </= 2 (Karnofsky >/= 60%; Lansky Score >/= 50).
  • Patients must have normal organ and marrow function defined as: absolute neutrophil count >/=1,000/mL; platelets >/=50,000/mL; creatinine < 2.0; total bilirubin < 2.0; ALT(SGPT) </= 3 X ULN; Exception for patients with liver metastasis: ALT(SGPT) </= 5 X ULN.
  • Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 30 days after the last dose.
  • Ability to understand and the willingness to sign a written informed consent document.

Who cannot join

  • Patients with uncontrolled concurrent illness, including but not limited to: ongoing or active infection requiring hospitalization; psychiatric illness/social situations that would limit compliance with study requirements.
  • Exclusion of patients with creatinine >2.0 and bilirubin > 2.0.
  • Pregnant or lactating women.
  • Patients with a history of bone marrow transplant within the previous two years.
  • Patients with a known hypersensitivity to any of the components of the drug products.
  • Patients with major surgery within 30 days prior to entering the study.
  • Patients with a baseline QTc > 500 ms.
  • Patients who are unable to swallow pills.

Trial locations and contacts

1 site in 1 country.

United States1 site

  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: A Phase I Dose-Escalation Study of the BRAF Inhibitor Vemurafenib (Zelboraf®) in Combination With an mTOR Inhibitor, Everolimus (Afinitor®) or Temsirolimus (Torisel®), in Subjects With Advanced Cancer

The goal of this clinical research study is to find the highest tolerable dose of vemurafenib that can be given in combination with either everolimus or temsirolimus. The safety of these drug combinations will also be studied.

Vemurafenib is designed to block BRAF inside the cancer cells, which is a mutation that is involved in cancer cell growth.

Temsirolimus and everolimus are designed to block the growth of cancer cells, which may cause cancer cells to die.

Read the detailed description

Study Drug Administration:

If you are found to be eligible to take part in this study, your doctor will decide whether you will receive either everolimus or temsirolimus

You will be assigned to a dose level of vemurafenib based on when you join this study. Up to 5 dose levels of vemurafenib will be tested. Up to 6 participants will be enrolled at each dose level. The first group of participants will receive the lowest dose level. Each new group will receive a higher dose than the group before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of vemurafenib is found.

Study Drug Administration:

You will take 3 vemurafenib tablets in the morning and 3 tablets in the evening.You will take it every day during each 28-day study cycle. You will take vemurafenib in combination with either 1 tablet of everolimus every day of each cycle or you will receive temsirolimus by vein over 30-60 minutes on Days 1, 8, 15, and 22 of each cycle.

You will receive a dosing diary to record ONLY the date and times when you did NOT take a scheduled dose of the study drug. You should bring this diary and any used or unused study drug bottles to your next study visit (even empty bottles must be returned).

Study Visits:

At all study visits, you will be asked about any drugs you may be taking and if you have had any side effects from them.

On Days 1 and 15 of Cycle 1 and Day 1 of Cycle 6:

  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.
  • You will have an ECG (Day 15 only)

On Day 1 of Cycles 2 and 5:

  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.
  • You will have an ECG.
  • Your skin will be checked.
  • You will have a CT scan or MRI scan to check the status of the disease (Cycle 5 only).

On Day 1 of Cycle 3:

  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.
  • You will have an ECG.
  • You will have a CT scan or MRI scan to check the status of the disease.

On Day 1 of Cycle 4:

  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.
  • You will have an ECG.
  • You will have a head and neck exam to check the status of the disease.

On Day 1 of Cycle 7:

  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.
  • You will have a CT scan or MRI scan to check the status of the disease.
  • You will have a head and neck exam to check the status of the disease.

On Day 1 of Cycles 8 and beyond:

  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.

After Cycle 7, every 12 weeks:

  • You will have an ECG.
  • You will have a head and neck exam to check the status of the disease.
  • Your skin will be checked.

On Day 1 of every 2 cycles:

°You will have a CT scan or MRI scan to check the status of the disease.

Length of Study:

You may continue taking the study drugs for as long as the doctor thinks it is in your best interest. You will no longer be able to take the study drugs if the disease gets worse, if intolerable side effects occur, or if you are unable to follow study directions.

Your participation on the study will be over once you have completed the follow-up.

End of Study Drug Dosing Visit:

Once you are no longer taking the study drug, you will have a study visit. At this visit:

  • You will be asked about any drugs you may be taking and if you have had any side effects from them.
  • You will have a physical exam, including measurement of your vital signs.
  • Your performance status will be recorded.
  • Blood (about 3 teaspoons) will be drawn for routine tests.
  • You will have an ECG.
  • You will have a CT scan or MRI scan to check the status of the disease.
  • Your skin will be checked.

Safety Follow-Up Visit:

If you leave the study for any reason other than the disease getting worse, you will have a follow-up visit about 28 days after your last dose. At this visit:

  • You will be asked about any drugs you may be taking and if you have had any side effects from them.
  • You will have an ECG.
  • Your skin will be checked.
  • You will have a head and neck exam to check the status of the disease.

Follow-Up:

Every 3 months after the last dose of study drug (for up to 12 months) you will be contacted by phone and asked about any new drugs you may be taking. This should take less than 5 minutes. This follow up may be during a regularly scheduled clinic visit.

Participant Responsibilities:

  • Take the study drug as instructed by the study staff.
  • Keep your study appointments. If you cannot keep an appointment, reschedule as soon as you know that you will miss the appointment.
  • Tell your doctor or study staff about any side effects, doctor visits, or hospitalizations that you may have.
  • Keep the study drug in a safe place, for your use only, and away from children. It must be stored at room temperature but not warmer than 77 degrees F (25 degrees Celsius).
  • Complete your diaries as instructed
  • While on this study, you cannot take part in any other research project without approval from your doctor.

This is an investigational study. Vemurafenib is FDA-approved for metastatic melanoma. Its use in other types of cancer is investigational. Everolimus and temsirolimus are FDA approved kidney cancer. The combination of these drugs is investigational.

Up to 114 participants will be enrolled in this study. All will take part at MD Anderson.

Being tested
Vemurafenib, Everolimus, Temsirolimus
Keywords
Vemurafenib, Everolimus, Afinitor, RAD001, temsirolimus, BRAF gene mutation, solid tumor, relapsed BRAF mutation positive malignant melanoma, refractory BRAF mutation positive malignant melanoma

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VemurafenibDrug

    Also called Zelboraf®, PLX4032, RO5185426

    Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.

  • EverolimusDrug

    Also called Afinitor®, RAD001

    Starting dose 5.0 mg by mouth daily for 28-day study cycle.

  • TemsirolimusDrug

    Also called Temodar

    Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.

Study groups in NCT01596140
Study groupRoleWhat they receive
Vemurafenib + Oral EverolimusExperimentalVemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Oral Everolimus starting dose 5 mg daily.
Receives: Drug: Vemurafenib; Drug: Everolimus
Vemurafenib + Intravenous TemsirolimusExperimentalVemurafenib starting dose 720 mg orally twice day (morning/evening) for 28-day cycle plus Intravenous Temsirolimus starting dose 15 mg daily on Days 1, 8, 15, and 22 of each cycle.
Receives: Drug: Vemurafenib; Drug: Temsirolimus

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Maximum Tolerated Dose (MTD) of Combination Vemurafenib

    The MTD of combination Vemurafenib and Everolimus or Vemurafenib and Temsirolimus is defined as the highest dose studied in which the incidence of dose limiting toxicity (DLT) was less than one third (33%) of the participants at that dose level. DLT defined as any Grade 3 or 4 non-hematologic toxicity, as defined in NCI CTC v4.0, even if expected and believed related to study medications, any Grade 4 hematologic toxicity lasting two weeks or longer despite supportive care; Grade 3 nausea/vomiting > 48 hours or any Grade 4 nausea/vomiting; and any other Grade 3 non-hematologic toxicity, including symptoms/signs of vascular leak or cytokine release syndrome; or any severe or life-threatening complication or abnormality not defined in NCI-CTCAE that is attributable to therapy.

    Measured: First cycle of 28 day cycle

Secondary outcomes (1)

  1. Tumor Response

    Tumor response defined as one or more of the following: (1) stable disease for more than or equal to 4 months, (2) decrease in measurable tumor (sentinel lesions) by more than or equal to 20% by RECIST criteria, (3) decrease in tumor markers by more than or equal to 25% (for example, a >/= 25% decrease in CA125 for patients with ovarian cancer), or (4) a partial response according to Choi criteria, i.e., decrease in size by 10% or more, or a decrease in tumor density, as measured in Hounsfield units (HU), by more than or equal to 15%.

    Measured: 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2012 (estimated)
  2. Study start18 Dec 2012
  3. Primary completion1 Jun 2020
  4. Study completion1 Jun 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01596140
Sponsor's protocol ID
2012-0153
Other IDs
NCI-2012-00789
Status last verified
Jun 2020
First submitted
8 May 2012
Last updated
4 Jun 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Vemurafenib, Everolimus and Temsirolimus in people with Advanced Cancer and Solid Tumor, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Maximum Tolerated Dose (MTD) of Combination Vemurafenib (time frame: First cycle of 28 day cycle). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT01596140.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2020; AzTrials last refreshed its copy on 8 Nov 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in